AMBS - Amarantus BioScience Holdings, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0192
+0.0006 (+3.51%)
As of 10:17AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0185
Open0.0195
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0192 - 0.0195
52 Week Range0.0151 - 0.0765
Volume10,150
Avg. Volume379,364
Market Cap3.336M
Beta (3Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-2.7280
Earnings DateAug 18, 2016 - Aug 19, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis

    REHOVOT, Israel, July 15, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostic company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease (AD), today announced positive results from a pre-specified interim analysis of 20 subjects from an ongoing 40-subject outpatient study evaluating the relationship between LymPro Test™ (LymPro) scores with amyloid PET imaging scores. The study is being conducted under the direction of Dr. Thomas Arendt at the University of Leipzig in Germany, with mild cognitive impairment (MCI) and dementia patients evaluated in the clinic of the Neurobiological Research group in the Department of Psychiatry and Psychotherapy. Todos Medical expects Leipzig to complete patient enrollment in the second half of 2019, and to disclose full results in a future scientific conference.

  • GlobeNewswire6 days ago

    Todos Medical Announces Launch of Public Offering

    REHOVOT, Israel, July 11, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has launched a roadshow for a public offering of up to $7,000,000 of units.  Each unit issued in the offering will consist of one share of common stock and one warrant to purchase one share of common stock.  The common stock and warrants will be immediately separable from the units and will be issued separately.

  • GlobeNewswire20 days ago

    Todos Medical to Sponsor the Investacure ‘Cure Coin Awards Reception’ for Alzheimer’s and CTE Research at AAIC 2019 in Los Angeles

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it will be sponsoring the Investacure ‘Cure Coin Awards Reception’ on Monday, July 15, 2019, at 7 p.m. at The Association, 110 East 6th Street, in downtown Los Angeles, CA. The reception is being hosted to honor researchers in Alzheimer’s and CTE who are working to turn scientific discoveries into clinical interventions that could alter the course of those two devastating neurodegenerative diseases. Todos Medical intends to release preliminary data regarding the LymPro Test’s utility for the detection of Alzheimer’s, based upon studies conducted at Leipzig University on the comparability of LymPro and amyloid PET imaging.

  • GlobeNewswire22 days ago

    Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation

    NEW YORK, NY, June 25, 2019 -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding.

  • GlobeNewswire29 days ago

    Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association

    NEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that positive results from in vitro and animal studies on MANF in the treatment of Wolfram Syndrome were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.

  • GlobeNewswirelast month

    Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that CEO Herman Weiss, MD, MBA, FACOG, provided a corporate update and roadmap at  LD Micro International Annual Invitational in Los Angelos, California. From our flagship TBIA platform, our TM-B2 test is a blood test for breast cancer initially focused on replacing the current battery of tests performed on patients with dense breasts who have inconclusive mammogram results, a significant unmet medical need.

  • GlobeNewswirelast month

    Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics

    New York, NY, June 13, 2019 -- via NEWEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding.

  • GlobeNewswirelast month

    Amarantus to Present at 9th Annual LD Micro Invitational Conference

    New York, NY, June 04, 2019 -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding.

  • GlobeNewswirelast month

    Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts

    Todos Medical Ltd. (TOMDF) (http://www.Todosmedical.com) today announced positive results from a clinical trial completed at CGH Hospital in Singapore. The study was focused primarily on subjects of Asian descent, a population in which women have the highest rate of dense breast tissue. The current standard of care is estimated to range from 50% accuracy in women with dense breasts and  an accuracy rate of 75% in the standard population.

  • GlobeNewswire2 months ago

    Amarantus Releases Letter to Shareholders

    First, thank you for your continued support of the Company. With new data on our Alzheimer’s diagnostic blood test ‘LymPro’ in hand from Dr. Thomas Arendt’s lab at Leipzig University, our Joint Venture Partner Todos Medical, Ltd. (TOMDF) has exercised their exclusive option to acquire the remaining 80.01% of Amarantus’ subsidiary Breakthrough Diagnostics, Inc. Upon closing of the transaction, Amarantus will be a major shareholder in Todos, an exciting immune-based cancer diagnostics company based in Israel, headed by Herman Weiss, MD, former Global Medical Director of Women’s Health and Bone Health at Teva Pharmaceutical Industries, Ltd. With technology out of Ben-Gurion University, Todos is harnessing a unique understanding of the immune system to develop biomarker-based products to address key unmet needs in cancer.

  • GlobeNewswire2 months ago

    Amarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Emerging Legal Hemp Industry

    New York, NY, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that it has engaged Evolution Venture Partners (www.evovp.com), a crossover-focused biopharmaceutical advisory and investment firm that is expanding its business into the legal cannabis sector, to assist the Company in evaluating potential business opportunities and strategic alternatives in the emerging legal hemp industry. The engagement is for a period of six months, during which time the Company will continue to execute on its biopharmaceutical holding company financing and spinoff model while it evaluates launching or acquiring hemp-based operations.

  • GlobeNewswire2 months ago

    Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received and analyzed data from the University of Leipzig on the lymphocyte proliferation test (‘LymPro”), which demonstrated a strong correlation between LymPro and amyloid PET. Upon review of the LymPro data, Todos Medical exercised its exclusive option to acquire the remaining 80.01% of its joint venture Breakthrough Diagnostics from Amarantus Bioscience Holdings, Inc. (AMBS).

  • GlobeNewswire2 months ago

    Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received approval from the Israeli Ministry of Health (AMAR) to market and sell its breast cancer tests TM-B1 and TM-B2. “We are happy to achieve this important milestone approval from the Ministry of Health of the State of Israel. This approval, along with our recent signing of a distribution agreement for our cancer screens with Care GB in Israel, enables us to move forward at full strength to commercialize our products,” said Dr. Herman Weiss, CEO of Todos Medical.

  • GlobeNewswire2 months ago

    Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel

    Todos Medical Ltd. (TOMDF) a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders such as Alzheimer's disease, today announced the signing of a Distribution Agreement with Care G.B. Plus, Ltd. for exclusive distribution rights of Todos Medical Ltd.’s innovative and cost-effective TM-B2 blood tests for breast cancer screening in the State of Israel. “We recently have initiated commercialization of our breast cancer screen (TM-B1) in two European markets.

  • GlobeNewswire2 months ago

    Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that Todos Medical’s Annual Shareholder Meeting was held on Monday, April 29, 2019. “This has been an exciting year for Todos Medical as we have moved forward on many key initiatives.

  • GlobeNewswire3 months ago

    Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA)

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced it has received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) covering the use of its’ proprietary TBIA (Todos Biochemical Infrared Analysis) to detect the presence of a solid tumor in the lung. The approved claims cover the use of isolating, drying and measuring an infrared (IR) spectrum of dried blood plasma to identify the presence of a cancerous tumor in the lung. “There is a significant unmet medical need for the early detection of lung cancer, for which there are currently no diagnostic tests approved.

  • GlobeNewswire3 months ago

    Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries

    Todos Medical Ltd. (TOMDF) a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders such as Alzheimer's disease, today announced the signing of a Distribution Agreement with Orot+, the operational division of Orot-Luces (http://orot-luces.com), for exclusive distribution rights of Todos Medical Ltd.’s innovative and cost-effectiveTM-B2 blood tests for breast cancer screening in the European territories of Romania and Austria. “Since inception, Todos Medical has worked diligently to bring our breast cancer screening technology to commercialization to help patients and their physicians identify cancer earlier in the disease process using a simple blood test,” said Dr. Herman Weiss, Todos Medical’s CEO.

  • GlobeNewswire3 months ago

    Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0

    REHOVOT, Israel and NEW YORK, April 08, 2019 -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for.

  • GlobeNewswire5 months ago

    Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced that it has raised $1,350,500 from private investors (see Todos Medical’s Form 6-K filed on February 28, 2019). With financing secured, Todos Medical has closed the Joint Venture transaction with Amarantus Bioscience whereby Todos Medical issued to Amarantus 19.99% of the outstanding ordinary shares of Todos Medical, in exchange for 19.99% of Amarantus’s wholly-owned subsidiary Breakthrough Diagnostics, Inc.  In addition, as part of the transaction, Amarantus has assigned to Breakthrough Diagnostics all of Amarantus’s rights to the LymPro Test®, an immune-based neurodiagnostic blood test for detection of Alzheimer’s disease, and other diagnostic assets.  Breakthrough Diagnostics will focus on the development of the LymPro Test, which was originally developed at the University of Leipzig.

  • GlobeNewswire6 months ago

    MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan

    New York, NY, Jan. 17, 2019 -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development.

  • GlobeNewswire6 months ago

    MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa

    New York, NY, Jan. 15, 2019 -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development.

  • CNW Group6 months ago

    Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries

    Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries

  • GlobeNewswire6 months ago

    Amarantus Provides 2019 Roadmap

    NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today provided an update on its turnaround plan as senior management prepares to attend key events surrounding the JP Morgan Healthcare Conference in San Francisco. To this end, we have been working on executing partnerships and asset sales, while simultaneously negotiating down existing obligations.

  • GlobeNewswire7 months ago

    Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0

    Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced that it has entered into a Joint Venture Agreement (JV Agreement) with biotechnology holding company Amarantus Bioscience Holdings, Inc. (AMBS) to develop LymPro Test® as a diagnostic blood test for Alzheimer’s disease. LymPro Test is an immune-based neurodiagnostic blood test originally developed at Leipzig University in Germany.